G/MA/QR/N/GBR/1/Add.1  
24 de febrero  de 2022 
(22-1804) Página: 1/6 
Comité de Acceso a los Mercados  Original:  inglés  
 
  
NOTIFICACIÓN DE CONFORMIDAD CON LA DECISIÓN SOBRE  
EL PROCEDIMIENTO DE NOTIFICACIÓN DE RESTRICCIONES  
CUANTITATIVAS (G/L/59/REV.1)  
REINO UNIDO 
Addendum  
La siguiente comunicación, de fecha 24 de febrero de 2022 , se distribuye a petición de la delegación 
del Reino Unido.  
 
A. Miembro notificante : Reino Unido  
B. Fecha de la notificación : 17 de febrero de 2022  
C. Primera  notificación:  
 Sí 
 No, la última notificación se presentó con la signatura (signatura del documento) : 
G/MA/QR/N/GBR/1  
D. Tipo de notificación:  
 1. Completa (es decir, notificación de todas las restricciones cuantitativas en vigor)  
 2. Cambios de una notificación presentada anteriormente con la signatura 
G/MA/QR/N/GBR/1 consistentes en lo siguiente:  
 2.1 Establecimiento de nuevas restricciones, enumeradas en la sección 1.  
 2.2 Eliminación de restricciones, como se describe e n la casilla G infra.  
 2.3 Modificación de una restricción notificada anteriormente, como se indica en l a 
sección 1.  
 3. Notificación inversa de restricciones mantenidas por (Miembro):  
E. La notificación proporciona información sobre el siguiente período bienal 
(por ejemplo, 2012 -2014) : 2020-2022 y se refiere a restricciones en vigor al  
16 de diciembre de 2021  
F. La presente notificación contiene información* relativa a:  
 Sección 1 : Lista de restricciones cuantitativas actualmente en vigor.  
 Sección 2 : Referencia a otras notificaciones presentadas a la OMC que contengan 
información sobre restricciones cuantitativas actualmente en vigor e 
información adicional.  
 
* En inglés solamente.  G/MA/QR/N/GBR/1/Add.1  
- 2 - 
  G. Observaciones de carácter general, con inclusión de una descripción de la 
eliminación de restricciones notificada en el apartado 2.2 de la casilla D y la fecha 
en que esas restricciones dejaron de estar en vigor.  
1. El presente addendum  modifica el documento G/MA/QR/N/GBR/1 mediant e la notificación 
de la restricción cuantitativa nº 1, que actualiza y sustituye a la restricción cuantitativa nº  21 
notificada anteriormente en la Sección 1 del documento G/MA/QR/N/GBR/1. En esta 
notificación se actualiza la lista de códigos de productos aplicables a los medicamentos 
abarcados y se facilita más información sobre la forma en que se aplican las medidas.  
2. El Reino Unido notifica la reducción neta de 76 medicamentos de la lista de medicamentos 
necesarios para apoyar el tratamiento de pacientes del Reino Unido en un momento en que 
la COVID -19 sigue teniendo un efecto real tanto en la demanda como en la oferta de 
medicamentos, cuya exportación está sujeta a restricciones en determinadas circunstancias 
limitadas cuando esos medicamentos y a están en la cadena de suministro del Reino Unido 
y destinados a pacientes del Reino Unido.  
3. Se trata de medidas temporales, adoptadas con el fin de aliviar una escasez crítica de 
medicamentos necesarios para proteger la salud humana. Las medidas se exa minan 
periódicamente y solo se aplican cuando la necesidad crítica no puede satisfacerse mediante 
medidas alternativas. El 3 de agosto de 2021 se retiraron de la lista 30 medicamentos. 
Al 16 de diciembre de 2021, se habían retirado de la lista otros 47 med icamentos. Se ha 
añadido un medicamento a la lista.  
4. La notificación G/MA/QR/N/GBR/1 del Reino Unido incluía detalles relativos a Irlanda del 
Norte. La presente notificación no modifica dichos detalles, que siguen aplicándose.  
   
  G/MA/QR/N/GBR/1/Add.1  
- 3 - 
 
Section 1 : List of quantitative restrictions that are currently in force  
 
QR 
No. General description 
of the restriction  Type of 
restriction  Tariff line 
code(s) affected, 
based on HS 
(2017)  
ANNEX 2017  Detailed Product 
Description  WTO Justification and 
Grounds for 
Restriction, e.g.,  
Other International 
Commitments  National legal basis 
and entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
1 Measures to regulate 
exports of certain 
medicaments.  CP-X Medicines fall 
under the following 
commodity codes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3002.15.00 .00 1. H eading 3002 - 
Classification  
Human blood ; animal blood 
prepared for therapeutic, 
prophylactic or diagnostic 
uses; antisera, other blood 
fractions and immunological 
products, whether or not 
modified or obtained by 
means of biotechnological  
processes ; vaccines, toxins, 
cultures of micro -organisms 
(excluding yeasts) and 
similar products ; c ell 
cultures, whether or not 
modified  
 
 
 
Product Description per 
Commodity Code under 
Heading 3002  
Immunological products, 
put up in measured doses or 
in forms or packings for 
retail sale  Article XX(b) GATT  
Protection of human, 
animal or plant life or 
health.  Regulation 43(2) of the 
Human Medicines 
Regulations 2012 
requiring wholesale 
dealers to ensure 
continued supply of 
medicinal products so that 
the needs of patients in 
the UK are met . Further 
details can be found 
through: 
https://www.legislation.g
ov.uk/uksi/2012/1916/co
ntents/made  
 
The date restrictions came 
into effect va ries by 
medicine ; this is specified 
for each medicine on the 
list, updated on 16 
December 2021 and 
available on gov.uk at  
https://assets.publishing.
service.gov.uk/governme
nt/uploads/system/uploa
ds/attachment_data/file/
1042790/restricted -
medicines -list-december -
2021-v3.csv/preview  The list of medicines is 
maintained by the 
Department of  Health 
and Social Care.  
 
These measures are 
reviewed regularly.  
A full change log of 
previous measures, 
from October 2019, can 
be found here:  
https://www.gov.uk/go
vernment/publications/
medicines -that-cannot -
be-parallel -exported -
from-the-uk 
 
Medicines included on 
this list mee t the 
following conditions:  
• the medicine is 
required to meet 
the needs of UK 
patients  
• the medicine is 
either being 
exported or is at 
threat of being 
exported    
  G/MA/QR/N/GBR/1/Add.1  
- 4 - 
 
QR 
No. General description 
of the restriction  Type of 
restriction  Tariff line 
code(s) affected, 
based on HS 
(2017)  
ANNEX 2017  Detailed Product 
Description  WTO Justification and 
Grounds for 
Restriction, e.g.,  
Other International 
Commitments  National legal basis 
and entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
    
 
 
 
 
 
 
 
 
 2. H eading 3004 - 
Classification  
Medicaments consisting of 
mixed or unmixed products 
for therapeutic or 
prophylactic uses, put up in 
measured doses (including 
those in the form of 
transdermal administration 
systems) or in forms or 
packings for retail sale    • the export of the 
medicine is either 
contributing to, or 
may contribute to , 
a shortage of that 
medicine in the UK.  
 
Medicines on this list 
which have been 
produced to fulfil 
contracts overseas are 
not subject to  
    
 
 
3004.20.00  
3004.31.00  
3004.32.00  
 
3004.39.00  
3004.49.00  Product Description per 
Commodity Code under 
Heading 3004  
Other, containing antibiotics  
Containing insulin  
Containing corticosteroid 
hormones, their derivatives 
or structural analogues  
Other  
Other    restriction . A s such, 
restrictions only apply to 
wholesaler dealer 
license holders that are 
not the ma rket 
authorisation holder for 
a medicine intended for 
export . The measures 
are designed to ensure 
wholesalers fulfil their 
legal obligations to 
maintain supply to UK 
patients.    
  G/MA/QR/N/GBR/1/Add.1  
- 5 - 
 
QR 
No. General description 
of the restriction  Type of 
restriction  Tariff line 
code(s) affected, 
based on HS 
(2017)  
ANNEX 2017  Detailed Product 
Description  WTO Justification and 
Grounds for 
Restriction, e.g.,  
Other International 
Commitments  National legal basis 
and entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
       These restrictions are 
only applied and 
maintained where  
    Further detail of these 
medicines can be found at  
https://www.gov.uk/govern
ment/publications/medicine
s-that-cannot -be-parallel -
exported -from-the-uk 
 
These restrictions apply in 
certain circumstances to 
exports of specified 
medicines which are placed 
on the UK market for UK 
patients and needed to 
protect human health, 
including to treat Covid -19, 
inter alia.    alternative measures 
are not conside red 
sufficient on their own to 
ensure that UK supply 
meets demand.  
A number of exemptions 
apply to medicines in 
scope of these 
restrictions . F or 
example, exports 
destined for 
international 
humanitarian 
organisations such as 
COVAX are not covered . 
A full list of exemptions 
can be found at 
https://www.gov.uk/go
vernment/publications/
medicines -that-cannot -
be-parallel -exported -
from-the-uk 
 
Requests for exemptions 
are considered on a 
case-by-case basis. 
These can be submitted 
by a foreign government 
or government agency, 
or a wholesaler on their 
behalf at 
restrictedmedicines@dh
sc.gov.u k   
  G/MA/QR/N/GBR/1/Add.1  
- 6 - 
 
QR 
No. General description 
of the restriction  Type of 
restriction  Tariff line 
code(s) affected, 
based on HS 
(2017)  
ANNEX 2017  Detailed Product 
Description  WTO Justification and 
Grounds for 
Restriction, e.g.,  
Other International 
Commitments  National legal basis 
and entry into force  Administration, 
modification of 
previously notified 
measures, and other 
comments  
1 2 3 4 5 6 7 
        
Further information on 
these measures is 
available here:  
https://www.gov.uk/gui
dance/parallel -export -
and-hoarding -of-
restricted -medicines  
 
It is the responsibility of 
the wholesaler to ensure 
any exports are made or 
withheld in compliance 
with these restrictions. 
Failure to comply with 
these restrictions may 
lead to regulatory action 
by the Medicines and 
Healthcare products 
Regulatory Authority 
(MHRA) against the  
wholesale dealer's 
licence.  
There are no additional 
steps or declarations 
required from a customs 
perspective.  
__________